Wedge Capital Management L L P NC Has $41.60 Million Stake in Pfizer Inc. (NYSE:PFE)

Share on StockTwits

Wedge Capital Management L L P NC raised its position in Pfizer Inc. (NYSE:PFE) by 8,853.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,061,826 shares of the biopharmaceutical company’s stock after buying an additional 1,049,967 shares during the quarter. Wedge Capital Management L L P NC’s holdings in Pfizer were worth $41,602,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Morgan Stanley boosted its position in Pfizer by 2.4% in the second quarter. Morgan Stanley now owns 46,536,777 shares of the biopharmaceutical company’s stock valued at $2,015,972,000 after buying an additional 1,071,897 shares in the last quarter. Fisher Asset Management LLC grew its stake in shares of Pfizer by 2.6% during the third quarter. Fisher Asset Management LLC now owns 45,291,398 shares of the biopharmaceutical company’s stock worth $1,627,320,000 after buying an additional 1,158,147 shares during the last quarter. Nuveen Asset Management LLC increased its holdings in shares of Pfizer by 2,240.5% during the second quarter. Nuveen Asset Management LLC now owns 36,086,254 shares of the biopharmaceutical company’s stock worth $1,563,256,000 after buying an additional 34,544,423 shares in the last quarter. California Public Employees Retirement System increased its holdings in shares of Pfizer by 5.3% during the second quarter. California Public Employees Retirement System now owns 23,186,244 shares of the biopharmaceutical company’s stock worth $1,004,428,000 after buying an additional 1,159,857 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its stake in shares of Pfizer by 1.7% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 22,492,988 shares of the biopharmaceutical company’s stock valued at $808,173,000 after acquiring an additional 369,603 shares during the last quarter. 70.21% of the stock is currently owned by hedge funds and other institutional investors.

NYSE PFE opened at $40.67 on Thursday. The company has a market capitalization of $221.75 billion, a price-to-earnings ratio of 13.56, a PEG ratio of 4.24 and a beta of 0.65. Pfizer Inc. has a twelve month low of $33.97 and a twelve month high of $44.56. The stock has a fifty day simple moving average of $38.90 and a 200 day simple moving average of $38.18. The company has a quick ratio of 0.68, a current ratio of 0.90 and a debt-to-equity ratio of 0.55.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.13. Pfizer had a return on equity of 28.10% and a net margin of 30.57%. The firm had revenue of $12.68 billion for the quarter, compared to the consensus estimate of $12.37 billion. During the same period in the previous year, the business earned $0.78 EPS. The business’s quarterly revenue was down 4.6% compared to the same quarter last year. Research analysts expect that Pfizer Inc. will post 2.97 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 31st will be paid a $0.38 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.36. The ex-dividend date is Thursday, January 30th. This represents a $1.52 annualized dividend and a dividend yield of 3.74%. Pfizer’s dividend payout ratio is presently 48.00%.

Several equities research analysts recently weighed in on the company. ValuEngine raised Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Bank of America started coverage on Pfizer in a research report on Wednesday, October 16th. They set a “neutral” rating and a $37.00 price objective on the stock. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Pfizer in a report on Tuesday, October 29th. Royal Bank of Canada assumed coverage on Pfizer in a report on Monday, January 6th. They issued an “outperform” rating and a $46.00 target price for the company. Finally, Zacks Investment Research upgraded Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 target price for the company in a research report on Tuesday, October 1st. Nine analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $43.41.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Article: What is Forex?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.